Skip to main content
. 2019 Oct 24;8(11):1777. doi: 10.3390/jcm8111777

Figure 2.

Figure 2

Number of different neuromuscular adverse events (A), frequency distribution of underlying ICI-therapy (B), and outcome after neuromuscular adverse events (C) in analysed case reports of ICI-mediated neurological adverse events. CIDP: Chronic inflammatory demyelinating polyneuropathy; GBS: Guillain-Barré syndrome; ICI: Immune-checkpoint inhibitor; Ipi: Ipilimumab; Nivo: Nivolumab; Pembro: Pembrolizumab.